1-20 of 155
Daniel J. DeAngelo, MD
Close
Sort by
Journal Articles

Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Naveen Pemmaraju, MD, Giovanni Martinelli, MD, Elisabetta Todisco, MDPhD, Andrew A Lane, MD PhD, Evelyn Acuña-Cruz, MD, Eric Deconinck, MDPhD, Eunice S. Wang, MD, Kendra L. Sweet, MD MS, David A Rizzieri, MD, Luca Mazzarella, MDPhD, Daniel J. DeAngelo, MD PhD, Pau Montesinos, MD PhD, Corrado Tarella, Harry P. Erba, MD PhD, Marina Konopleva, MD PhD, Hagop M. Kantarjian, MD, Callum M Sloss, PhD, Kara E Malcolm, RN, Patrick A Zweidler-McKay, MDPhD, Naval Daver, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 11–13.
https://doi.org/10.1182/blood-2020-139903
Published: 2020
Journal Articles

Safety and Efficacy of Decitabine Plus Ipilimumab in Relapsed or Refractory MDS/AML in the Post-BMT or Transplant Naïve Settings

Jacqueline S. Garcia, MD, Yael Flamand, MS, Benjamin K. Tomlinson, MD, Michael Keng, MD, Lourdes M. Mendez, MD PhD, Samer Khaled, MD, Asad Bashey, MD PhD, Andrew M. Brunner, MD, Alexandra Savell, BS, Donna Neuberg, Ilene Galinsky, Marlise R. Luskin, MD, David P. Steensma, MD, Martha Wadleigh, MD, Eric S. Winer, MD, David E. Avigan, MD, Nicole Cullen, Scott Rodig, MD PhD, Livius Penter, R. Coleman Lindsley, MD PhD, Stephanie Andrews, Matthew S. Davids, MD, Catherine J. Wu, MD, Richard M. Stone, MD, Daniel J. DeAngelo, MD PhD, Robert J. Soiffer, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 15–17.
https://doi.org/10.1182/blood-2020-136235
Published: 2020
Journal Articles

Pioneer Part 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib in Indolent Systemic Mastocytosis

Cem Akin, MDPhD, Hanneke Oude Elberink, MD PhD, Jason Gotlib, MD MS, Vito Sabato, MD PhD, Karin Hartmann, MD, Sigurd Broesby-Olsen, MD, Mariana Castells, MD PhD, Tsewang Tashi, MD, Mark L Heaney, MD, Tracy I. George, MD, Frank Siebenhaar, MD, Deepti H. Radia, MRCPI, FRCPath, Massimo Triggiani, MD PhD, Paul van Daele, MD, Daniel J. DeAngelo, MD PhD, Iván Alvarez-Twose, MD PhD, Andreas Reiter, MD, Peter Vadas, MD PhD, Patrizia Bonadonna, MD, Paggy Hew, MS, Hui-Min Lin, PhD, Maria Roche, MS, Marcus Maurer, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 41–42.
https://doi.org/10.1182/blood-2020-136632
Published: 2020
Journal Articles

Efficacy and Safety of Ponatinib (PON) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Who Failed One or More Second-Generation (2G) Tyrosine Kinase Inhibitors (TKIs): Analyses Based on PACE and Optic

Hagop M. Kantarjian, MD, Michael W. Deininger, MD PhD, Elisabetta Abruzzese, MD, Jane Apperley, FRCP, FRCPath, MB, Jorge E. Cortes, MD, Charles Chuah, MD, Daniel J. DeAngelo, MD PhD, John F. DiPersio, MD PhD, Andreas Hochhaus, MD, Jeffrey H. Lipton, MD PhD, Franck E Nicolini, MDPhD, Javier Pinilla Ibarz, MD PhD, Delphine Rea, MDPhD, Gianantonio Rosti, MD, Philippe Rousselot, MDPhD, Neil P Shah, MD PhD, Moshe Talpaz, MD, Shouryadeep Srivastava, MBBS, PhD, Vickie Lu, PhD, Michael J. Mauro, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 43–44.
https://doi.org/10.1182/blood-2020-133922
Published: 2020
Journal Articles

Orthopedic Toxicity Among Adolescents and Young Adults Treated on DFCI ALL Consortium Trials

Yannis K. Valtis, MD, Kristen E. Stevenson, MS, Andrew E. Place, MDPhD, Lewis B. Silverman, MD, Lynda M. Vrooman, MD, Giacomo Gotti, MD, Andrew M. Brunner, MD, Mary Nauffel, Daniel J. DeAngelo, MD PhD, Marlise R Luskin, MDMS
Journal: Blood
Blood (2020) 136 (Supplement 1): 31–32.
https://doi.org/10.1182/blood-2020-137488
Published: 2020
Journal Articles

Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Hematopoietic Stem Cells in JAK2 -Mutant Myeloproliferative Neoplasms

Debra Van Egeren, Javier Escabi, *, Maximilian Nguyen, *, Shichen Liu, Christopher R. Reilly, MD, Sachin Patel, Baransel Kamaz, MD, Maria Kalyva, Daniel J. DeAngelo, MD PhD, Ilene Galinsky, Martha Wadleigh, MD, Eric S. Winer, MD, Marlise R Luskin, MDMS, Richard M. Stone, MD, Jacqueline S. Garcia, MD, Gabriela S. Hobbs, MD, Fernando D Camargo, PhD, Franziska Michor, PhD #, Ann Mullally, MD, Isidro Cortes-Ciriano, PhD #, Sahand Hormoz, PhD #
Journal: Blood
Blood (2020) 136 (Supplement 1): 7–8.
https://doi.org/10.1182/blood-2020-141643
Published: 2020
Journal Articles

Maximal Tolerated Dose of the BCL-2 Inhibitor Venetoclax in Combination with Daunorubicin/Cytarabine Induction in Previously Untreated Adults with Acute Myeloid Leukemia (AML)

Richard M. Stone, MD, Daniel J. DeAngelo, MD PhD, Anthony G. Letai, MD PhD, Jeremy M. Stewart, BA, Michael McGinnis, Francis Brown, JD, Geoffrey Fell, Yael Flammand, Marina Konopleva, MD PhD, Jacqueline S. Garcia, MD, Marlise R Luskin, MDMS
Journal: Blood
Blood (2020) 136 (Supplement 1): 40–41.
https://doi.org/10.1182/blood-2020-140646
Published: 2020
Journal Articles

Ameli-01: Phase I, Open Label Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of UCART123 (allogeneic engineered T-cells expressing anti-CD123 chimeric antigen receptor), Administered in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Gail J. Roboz, MD, Daniel J. DeAngelo, MD PhD, David A. Sallman, MD, Monica L. Guzman, PhD, Pinkal Desai, MDMPH, Hagop M. Kantarjian, MD, Marina Konopleva, MD PhD, Nelli Bejanyan, MD, Hany Elmariah, MD MS, Francisco Javier Esteva, MD PhD, Andrew Garton, Kate Backhouse, Roman Galetto, PhD, Carrie Brownstein, MD, Naveen Pemmaraju, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 41–42.
https://doi.org/10.1182/blood-2020-138984
Published: 2020
Journal Articles

A Phase 1b/2 Study of IMGN632, a CD123-Targeting Antibody-Drug Conjugate (ADC), As Monotherapy or in Combination with Venetoclax and/or Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia

Naval Daver, MD, Kendra L. Sweet, MD MS, Pau Montesinos, MD PhD, Eunice S. Wang, MD, Ahmed Aribi, MD, Daniel J. DeAngelo, MD PhD, Harry P Erba, MDPhD, Giovanni Martinelli, MD, Roland P Walter, MDPhD, Jessica K Altman, MD, Anjali S Advani, MD, Antonio Curti, MDPhD, Callum M Sloss, PhD, Kara E Malcolm, RN, Patrick A Zweidler-McKay, MDPhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 50–51.
https://doi.org/10.1182/blood-2020-139884
Published: 2020
Journal Articles

Safety and Efficacy of Adding Venetoclax to Reduced Intensity Conditioning Chemotherapy Prior to Allogeneic Hematopoietic Cell Transplantation in Patients with High Risk Myeloid Malignancies

Jacqueline S. Garcia, MD, Haesook Kim, Corey Cutler, MD MPH, FRCPC, Eric S. Winer, MD, Richard M. Stone, MD, Vincent T. Ho, MD, Rizwan Romee, MD, John Koreth, MBBS, DPhil, Mahasweta Gooptu, MD, Sarah Nikiforow, MD PhD, Roman M Shapiro, MD, David P. Steensma, MD, Marlise R. Luskin, MD, Martha Wadleigh, MD, Fiona Loschi, Jeremy Ryan, Anthony Letai, R. Coleman Lindsley, MD PhD, Jennifer Brock, Robert J. Soiffer, MD, Daniel J. DeAngelo, MD PhD, Joseph H. Antin, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 38–39.
https://doi.org/10.1182/blood-2020-134947
Published: 2020
Journal Articles

Pure Pathologic Response Is Associated with Improved Overall Survival in Patients with Advanced Systemic Mastocytosis Receiving Avapritinib in the Phase I EXPLORER Study

Jason Gotlib, MD MS, Deepti H. Radia, MRCPI, FRCPath, Tracy I. George, MD, William A Robinson, MD PhD, Albert T. Quiery, MD, Mark W. Drummond, PhD FRCPath, Prithviraj Bose, MD, Elizabeth O. Hexner, MD, Elliott F. Winton, MD, Hans-Peter Horny, Prof, Dr, Meera Tugnait, PhD, Oleg Schmidt-Kittler, PhD, Erica K. Evans, PhD, Hui-Min Lin, PhD, Brenton G. Mar, MD PhD, Michael W. Deininger, MD PhD, Daniel J. DeAngelo, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 37–38.
https://doi.org/10.1182/blood-2020-137413
Published: 2020
Journal Articles

Gene Expression Signature Predicts Deep Molecular Response (DMR) in Chronic Myeloid Leukemia (CML): An Exploratory Biomarker Analysis from ENESTnd

Jerald P. Radich, MD, Richard A. Larson, MD, Hagop M. Kantarjian, MD, Michael W. Deininger, Javier Pinilla Ibarz, MD PhD, Daniel J. DeAngelo, MD PhD, Susan Branford, PhD FFSc (RCPA), Islam Sadek, Shalini Chaturvedi, Manu Sondhi, MD PhD, Matthew Wall, Kaushal Mishra, PhD, Das Purkayastha, PhD, Alok Shrestha, Vanessa Obourn, Brian S. White, Brian J. Druker
Journal: Blood
Blood (2019) 134 (Supplement_1): 665.
https://doi.org/10.1182/blood-2019-124716
Published: 2019
Journal Articles

Management of CAR T-Cell Toxicities: Concordance and Divergence between Healthcare Providers and Expert Consensus Recommendations

Matthew Frigault, MD MSc, Megan Cartwright, PhD, Krista Marcello, BA, Timothy A Quill, PhD, Daniel J. DeAngelo, MD PhD, Ilene Galinsky, Shilpa Paul, PharmD, Jae H. Park, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2199.
https://doi.org/10.1182/blood-2019-131533
Published: 2019
Journal Articles

Clinical and Immunologic Activity of Ipilimumab Following Decitabine Priming in Post-Allogeneic Transplant and Transplant-Naïve Patients with Relapsed or Refractory Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Multi-Center Phase 1, Two-Arm, Dose-Escalation Study

Jacqueline S Garcia, MD, Lillian Werner, Benjamin K. Tomlinson, MD, Michael Keng, MD, Myrna Nahas, MD, Andrew Brunner, MD, Samer K. Khaled, MD, Alexandra Savell, BS, Marlise Luskin, MDMS, David P. Steensma, MD, Martha Wadleigh, MD, Eric S. Winer, MD, Edwin P. Alyea, III, MD, Corey Cutler, MD MPH, FRCPC, Vincent T. Ho, MD, Donna S Neuberg, ScD, Nicole Cullen, Andreas Kantartzis, Ana Lako, Scott Rodig, MD PhD, R. Coleman Lindsley, MD PhD, Yael Flamand, Claire Manuszak, Ryan Brennick, Mariano Severgnini, Stephanie Andrews, Ilene Galinsky, Pavan Bachireddy, MD, Yohei Arihara, MD PhD, Jerome Ritz, MD, Matthew S. Davids, MD, Howard Streicher, MD, Catherine J. Wu, MD, Richard M. Stone, MD, Daniel J. DeAngelo, MD, Robert J. Soiffer, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2015.
https://doi.org/10.1182/blood-2019-126238
Published: 2019
Journal Articles

Efficacy and Safety Outcomes in the Phase 3 INO-Vate Trial By Baseline CD22 Positivity Assessed By Local Laboratories

Hagop M. Kantarjian, MD, Wendy Stock, MD, Ryan D. Cassaday, MD, Daniel J. DeAngelo, MD PhD, Elias Jabbour, MD, Susan M. O'Brien, MD, Matthias Stelljes, MD, Tao Wang, M. Luisa Paccagnella, Kevin Nguyen, Barbara Sleight, MD, Erik R. Vandendries, MD PhD, Alexander Neuhof, MD, A. Douglas Laird, PhD, Anjali S. Advani, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1344.
https://doi.org/10.1182/blood-2019-122097
Published: 2019
Journal Articles

A Phase I Study of CC-90002, a Monoclonal Antibody Targeting CD47, in Patients with Relapsed and/or Refractory (R/R) Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS): Final Results

Amer M. Zeidan, MBBS, MHS, Daniel J. DeAngelo, MD PhD, Jeanne M. Palmer, Christopher S. Seet, MD PhD, Martin S. Tallman, MD, Xin Wei, PhD, Ying Fei Li, PhD, Nanette Hock, RN, MSN, Michael R. Burgess, Kristen Hege, Wendy Stock, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1320.
https://doi.org/10.1182/blood-2019-125363
Published: 2019
Journal Articles

Pioneer: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Avapritinib in Patients with Indolent or Smoldering Systemic Mastocytosis with Symptoms Inadequately Controlled with Standard Therapy

Cem Akin, MD PhD, Vito Sabato, Jason Gotlib, MD MS, Mariana Castells, Michael W. Deininger, Hanneke Oude Elberink, Mark L Heaney, Paul van Daele, Deepti Radia, Massimo Triggiani, Daniel J. DeAngelo, MD, Iván Alvarez-Twose, Sigurd Broesby-Olsen, Tracy I. George, MD, Karin Hartmann, Siebenhaar Frank, Andreas Reiter, Peter Vadas, Patrizia Bonadonna, Jens P. Panse, Petra Staubach-Renz, Knut Brockow, Diamant Thaci, Hui-Min Lin, Andrew Morrison, Brenton Mar, Marcus Maurer
Journal: Blood
Blood (2019) 134 (Supplement_1): 2950.
https://doi.org/10.1182/blood-2019-126035
Published: 2019
Journal Articles

High E-Selectin Ligand Expression Contributes to Chemotherapy-Resistance in Poor Risk Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML) Patients and Can be Overcome with the Addition of Uproleselan

Daniel J. DeAngelo, MD PhD, Brian A Jonas, MD PhD, Jane L. Liesveld, MD, Dale L. Bixby, MD, Anjali S. Advani, MD, Paula Marlton, MBBS (Hons), FRACP, FRCPA, Michael E O'Dwyer, MD, William E. Fogler, PhD, John L. Magnani, PhD, Mary M Chen, MD PhD, Eric J. Feldman, MD, Helen M Thackray, MD, Pamela S. Becker, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2690.
https://doi.org/10.1182/blood-2019-123744
Published: 2019
Journal Articles

A Phase 1b/2 Study of the CD123-Targeting Antibody-Drug Conjugate IMGN632 As Monotherapy or in Combination with Venetoclax and/or Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia

Naval G. Daver, MD, Harry P. Erba, MD PhD, Nikolaos Papadantonakis, MDPhDMSc, Daniel J. DeAngelo, MD, Eunice S. Wang, MD, Marina Y Konopleva, MD PhD, Callum M. Sloss, PhD, Jiuzhou Wang, PhD, Kara E. Malcolm, RN, Patrick A. Zweidler-McKay, MD PhD, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2601.
https://doi.org/10.1182/blood-2019-128501
Published: 2019
Journal Articles

Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical, Clinical, and Correlative Studies

Jacqueline S Garcia, MD, Helen I. Gandler, Geoffrey Fell, MS, Ashlee J. Fiore, Donna S Neuberg, ScD, Adrienne Anderson, Kelsey O'Day, Marlise Luskin, MDMS, Martha Wadleigh, MD, Eric S. Winer, MD, Ilene Galinsky, Daniel J. DeAngelo, MD, David A. Frank, MD PhD, Richard M. Stone, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2549.
https://doi.org/10.1182/blood-2019-126224
Published: 2019